The mission of the Cancer Center Peptide Synthesis and Design Core Facility is to (i) foster collaborations between Cancer Center investigators who utilize peptides in their research and (ii) provide peptides to support investigators' projects that involve protein-protein interactions for the study of tumor cell recognition of the extracellular matrix, cell differentiation, induction of cell signaling pathways and gene induction, and cancer immunology. The Peptide Synthesis Facility has also been developing novel peptides and analogs for use as anti-cancer therapeutics. These include: (i) conformationally constrained peptides and mini-proteins that are both resistant to proteolysis and specifically target tumor cell receptors and (ii) peptide-amphiphiles that form liposomes, which in turn are used as drug delivery vehicles targeted for tumor cell receptors. The Peptide Synthesis and Design Core Facility is composed of an Applied Biosystems 431A Peptide Synthesizer, a Gilson AMS 422 Multiple Peptide Synthesizer, a Beckman System 990 Peptide Synthesizer, an Applied Biosystems 477A Protein Sequencer/120A Analyzer, A Beckman P/ACE System 5000 Capillary Electrophoresis Apparatus, 2 Rainin preparative HPLC systems including fraction collectors, 2 Beckman System Gold preparative HPLC systems, and a Hewlett Packard Series II 1090 AminoWant HPLC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA077598-01
Application #
6269904
Study Section
Project Start
1998-06-01
Project End
1999-05-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Petzel, Sue V; Isaksson Vogel, Rachel; Cragg, Julie et al. (2018) Effects of web-based instruction and patient preferences on patient-reported outcomes and learning for women with advanced ovarian cancer: A randomized controlled trial. J Psychosoc Oncol 36:503-519
Lassig, Amy Anne D; Bechtold, Joan E; Lindgren, Bruce R et al. (2018) Tobacco exposure and wound healing in head and neck surgical wounds. Laryngoscope 128:618-625
Passow, Kellan T; Harki, Daniel A (2018) 4-Cyanoindole-2'-deoxyribonucleoside (4CIN): A Universal Fluorescent Nucleoside Analogue. Org Lett 20:4310-4313
Pierpont, Elizabeth I; McCoy, Erin; King, Kelly E et al. (2018) Post-transplant adaptive function in childhood cerebral adrenoleukodystrophy. Ann Clin Transl Neurol 5:252-261
Scott, Milcah C; Temiz, Nuri A; Sarver, Anne E et al. (2018) Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma. Cancer Res 78:326-337
Guo, Zhijun; Johnson, Veronica; Barrera, Jaime et al. (2018) Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them. Cancer Metastasis Rev 37:409-423
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Ho, Yen-Yi; Nhu Vo, Tien; Chu, Haitao et al. (2018) A Bayesian hierarchical model for demand curve analysis. Stat Methods Med Res 27:2038-2049
Ustun, C; Brunstein, C; DeFor, T et al. (2018) Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation. Bone Marrow Transplant 53:97-100
How, Joan; Vij, Kiran R; Ebadi, Maryam et al. (2018) Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol 93:E381-E383

Showing the most recent 10 out of 1013 publications